XML 281 R73.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Information - Schedule of Financial Information (Details) - USD ($)
 12 Months Ended
Mar. 04, 2024
Dec. 31, 2024
Dec. 31, 2023
Revenue, Major Customer [Line Items]      
Revenue   $ 1,000,000 $ 0
Operating Expenses:      
Research and development   11,334,000 12,734,000
General and administrative   12,075,000 12,974,000
Operating loss   (22,409,000) (25,708,000)
Other income (expense),net   (257,000) (186,000)
Benefit from income taxes $ 800,000 (798,000) (2,330,000)
Net loss   (19,985,000) (20,840,000)
Reportable Segment      
Revenue, Major Customer [Line Items]      
Revenue   1,000,000 0
Operating Expenses:      
Research and development   11,334,000 12,734,000
General and administrative   12,075,000 12,974,000
Investor relations/public relations/communications   1,332,000 898,000
Finance   2,265,000 2,421,000
Legal   1,284,000 1,292,000
Business development   582,000 1,474,000
Share based compensation expense   1,383,000 1,497,000
Other   1,536,000 1,536,000
Operating loss   (22,409,000) (25,708,000)
Other income (expense),net   1,626,000 2,538,000
Benefit from income taxes   (798,000) (2,330,000)
Net loss   (19,985,000) (20,840,000)
Cash and marketable securities   31,245,000 50,535,000
Reportable Segment | Segment Reporting, Reconciling Item, Corporate Nonsegment      
Operating Expenses:      
General and administrative   3,693,000 3,856,000
Reportable Segment | BOLSTER trial      
Operating Expenses:      
Research and development   3,581,000 3,517,000
Reportable Segment | ASCEND trial      
Operating Expenses:      
Research and development   754,000 1,155,000
Reportable Segment | Chemistry, manufacturing and controls      
Operating Expenses:      
Research and development   2,035,000 2,406,000
Reportable Segment | Clinical department      
Operating Expenses:      
Research and development   4,304,000 4,744,000
Reportable Segment | Other      
Operating Expenses:      
Research and development   $ 660,000 $ 912,000